Jubilant Pharmova’s Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The standalone results reveal a total revenue from operations of ₹673 million for the quarter. The company also successfully transferred its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited during the period. The consolidated revenue from operations stood at ₹21,225 million.
Standalone Financial Performance
The Board of Directors approved the unaudited standalone financial results for Q3 2026 on February 6, 2026. Key highlights include:
- Total revenue from operations for the quarter stood at ₹673 million.
- Profit before tax was reported at ₹101 million.
- Net profit after tax reached ₹66 million.
Furthermore, during the period, the company completed the slump sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, Jubilant Biosys Limited, effective September 1, 2025.
Consolidated Financial Highlights
The consolidated unaudited results reflect the broader performance of Jubilant Pharmova and its subsidiaries. Key figures include:
- Total revenue from operations reached ₹21,225 million.
- Profit before tax stood at ₹934 million.
- Net profit for the period was ₹558 million.
Segment Performance
A breakdown of segment-wise performance reveals the following asset distribution:
- Radiopharma assets: ₹31,651 million
- Allergy Immunotherapy assets: ₹6,076 million
- Contract Development and Manufacturing Organisation (Sterile Injectables) assets: ₹55,169 million
- Contract Research, Development and Manufacturing Organisation assets: ₹18,369 million
- Generics assets: ₹12,891 million
Source: BSE
